Specificity Improved for Urinary Antigen Testing
By LabMedica International staff writers Posted on 23 May 2017 |
Image: The Cryptococcal Antigen Lateral Flow Assay (CrAg LFA) Immy test (Photo courtesy of Immuno-Mycologics).
The cryptococcal antigen lateral flow assay (CrAg LFA) Immy test is standardized for a fast screening point-of-care test for cryptococcosis, detecting cryptococcal antigen in serum and cerebrospinal fluid (CSF).
A delay in laboratory diagnosis is related to sequelae and death and therefore early diagnosis is the key to decrease the high lethality rate due to cryptococcosis. Urine screening would be ideal as a noninvasive approach, but previous studies have shown that fresh urine present false positive results.
Scientists at the National Institute of Infectious Diseases Evandro Chagas performed a prospective cohort study from April 2014 to April 2015 on 77 volunteers: 53 HIV-positive (CD4+ T cell less than 200 cells/mm3) patients, 18 healthy individuals (negative controls), and six HIV-positive patients with active proven cryptococcosis (positive controls). Healthy individuals were included as a negative control and patients presenting proven cryptococcosis as a positive control.
Cryptococcal antigen testing was performed in blood serum and urine from each volunteer using the CrAg LFA Immy test. Each fresh urine sample was tested under two conditions: unheated (untreated) and heated (treated) by five minutes incubation at 100 °C. Clinical specimens such as blood, CSF, and urine were subsequently cultivated to investigate cryptococcal infection. The CrAg LFA in serum samples was considered as the gold standard.
The investigators reported that 24/53 HIV-positive volunteers had a CrAg LFA–positive profile (42.3%) when untreated fresh urine was tested. When heated, only eight samples were positive (15%), presenting 100% of agreement with the positive results obtained from serum samples submitted to CrAg LFA Immy assay. Out of those eight positive patients, five had proven cryptococcosis (positive culture for Cryptococcus neoformans in CSF and/or blood culture) and three patients had cryptococcal antigenemia (negative for Cryptococcus in blood and CSF cultures). The untreated fresh urine has shown 16 false positive results (30.2%). After treatment, those urine samples were negative, as confirmed by negative results in the serum.
The authors concluded that heating of urine prior testing dramatically improved the test’s specificity without compromising the test’s sensitivity. This crucial step has dramatically increased the specificity without compromising test sensitivity, with two additional advantages: no need of enzymatic treatment or sample dilution. The study was published on the journal Public Library of Science Neglected Tropical Diseases.
A delay in laboratory diagnosis is related to sequelae and death and therefore early diagnosis is the key to decrease the high lethality rate due to cryptococcosis. Urine screening would be ideal as a noninvasive approach, but previous studies have shown that fresh urine present false positive results.
Scientists at the National Institute of Infectious Diseases Evandro Chagas performed a prospective cohort study from April 2014 to April 2015 on 77 volunteers: 53 HIV-positive (CD4+ T cell less than 200 cells/mm3) patients, 18 healthy individuals (negative controls), and six HIV-positive patients with active proven cryptococcosis (positive controls). Healthy individuals were included as a negative control and patients presenting proven cryptococcosis as a positive control.
Cryptococcal antigen testing was performed in blood serum and urine from each volunteer using the CrAg LFA Immy test. Each fresh urine sample was tested under two conditions: unheated (untreated) and heated (treated) by five minutes incubation at 100 °C. Clinical specimens such as blood, CSF, and urine were subsequently cultivated to investigate cryptococcal infection. The CrAg LFA in serum samples was considered as the gold standard.
The investigators reported that 24/53 HIV-positive volunteers had a CrAg LFA–positive profile (42.3%) when untreated fresh urine was tested. When heated, only eight samples were positive (15%), presenting 100% of agreement with the positive results obtained from serum samples submitted to CrAg LFA Immy assay. Out of those eight positive patients, five had proven cryptococcosis (positive culture for Cryptococcus neoformans in CSF and/or blood culture) and three patients had cryptococcal antigenemia (negative for Cryptococcus in blood and CSF cultures). The untreated fresh urine has shown 16 false positive results (30.2%). After treatment, those urine samples were negative, as confirmed by negative results in the serum.
The authors concluded that heating of urine prior testing dramatically improved the test’s specificity without compromising the test’s sensitivity. This crucial step has dramatically increased the specificity without compromising test sensitivity, with two additional advantages: no need of enzymatic treatment or sample dilution. The study was published on the journal Public Library of Science Neglected Tropical Diseases.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms